Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders

References

• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
   PubMed Web of Science ®Google Scholar
• Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851-8
   PubMed Web of Science ®Google Scholar
• Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-42
   PubMedGoogle Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61(Suppl 2):10-12
   PubMed Web of Science ®Google Scholar
• Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-9
   Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Nichols AI, Tourian KA, Tse SY, et al. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol 2010;6:1565-74
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Germain J-M, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
   PubMed Web of Science ®Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008;23:188-97
   PubMed Web of Science ®Google Scholar
• World Medical Association Web site. Declaration of Helsinki. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html [Last accessed 2 April 2009]
   Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Washington, DC: American Psychiatric Association, 1994
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Guy W (ed.) Clinical Global Impressions. Publication ADM 76-338. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976:217-22
   Google Scholar
• Raskin A, Schulterbrandt J, Reatig N, et al. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 1969;148:87-98
   PubMed Web of Science ®Google Scholar
• Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 1982;18:69-77
   PubMedGoogle Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
   PubMed Web of Science ®Google Scholar
• Rickels K, Montgomery SA, Tourian KA, et al. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 2010;30:18-24
   PubMed Web of Science ®Google Scholar
• Pristiq [package insert]. Philadelphia, PA, USA: Wyeth Pharmaceuticals 2008
   Google Scholar
• Romera I, Montejo AL, Delgado-Cohen H, et al. Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: results from a Spanish sample. Int J Psychiatry Clin Pract 2009;13:100-8
   PubMed Web of Science ®Google Scholar
• de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-6
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000;20:483-7
   PubMed Web of Science ®Google Scholar
• Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006;26:250-8
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42
   PubMed Web of Science ®Google Scholar
• Wohlreich MM, Martinez JM, Mallinckrodt CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 2005;25:552-60
   PubMed Web of Science ®Google Scholar
• Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 2008;69:95-105
   PubMed Web of Science ®Google Scholar
• Effexor [package insert]. Philadelphia, PA, USA: Wyeth Pharmaceuticals, 2002
   Google Scholar
• Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. CYP2D6 phenotype predicts antidepressant efficacy of venlafaxine. J Clin Psychiatry 2010;71:1482-7
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Nichols AI, Paul J, et al. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008;14:368-78
   PubMed Web of Science ®Google Scholar
• Miner CM, Brown EB, Gonzales JS, et al. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry 2002;63:232-40
   PubMed Web of Science ®Google Scholar
• Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
   PubMed Web of Science ®Google Scholar
• Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Ann Clin Psychiatry 2005;17:259-68
   PubMedGoogle Scholar
• Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004;26:1446-55
   PubMed Web of Science ®Google Scholar
• Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63:577-84
   PubMed Web of Science ®Google Scholar